A special class of pharmaceutical drugs known as therapeutic peptides is composed of a series of amino acids with molecular weights ranging from 500 to 5000 Da. Peptide therapy is used to find new treatments and drugs. As a result, the market growth over the projected period is likely to be boosted by increasing research and development initiatives by major companies in the industry to expand their product range. The growing prevalence of cancer is projected to fuel market expansion during the forecast period because peptide therapeutics technology is utilized to treat cancer.
The global market for Peptide Therapeutics is anticipated to expand at a CAGR of 6.6% from 2023 to 2030.
Leading Companies in the Peptide Therapeutics Industry
1. Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd is an Israeli multinational pharmaceutical company, founded in 1901 and headquartered in Tel Aviv, Israel. It operates in more than 60 countries.
2. Novo Nordisk A/S
Novo Nordisk A/S is a Danish international pharmaceutical firm with its headquarters in Bagsvaerd, Denmark. It was established in 1923. 80 countries and territories are where it operates. In November 2021, Novo Nordisk will acquire Dicerna Pharmaceuticals, along with its RNAi research technology platform. The addition of Dicerna's RNAi platform to Novo Nordisk's existing research technology platforms is crucial and furthers the company's objective of leveraging a diversified collection of technology platforms that are relevant across all therapeutic emphasis areas.
3. Lilly
is an American pharmaceutical company, founded in 1876 and headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being tested for chronic weight management in obese or overweight individuals, orforglipron, had updated phase 2 results published by Eli Lilly and Company in June 2023. The results were released concurrently in the New England Journal of Medicine and verbally presented at the 83rd Scientific Sessions of the American Diabetes Association®. Orforglipron demonstrated clinically significant weight loss in patients with obesity or overweight who had at least one weight-related disease (apart from type 2 diabetes) and satisfied both primary and secondary efficacy objectives.
4. Sanofi
Sanofi was founded in 1973 and headquartered in Paris, France. It operates in more than 170 countries. In March 2023, Sanofi and Provention Bio, Inc. reached an agreement under which Sanofi agreed to acquire Provention Bio, a publicly traded biopharmaceutical company with headquarters in the United States that focuses on detecting and preventing immune-mediated illnesses like type 1 diabetes (T1D). Inc, for $25.00 per share in cash, which equates to an equity value of roughly $2.9 billion. With the addition of Provention Bio to the portfolio, TZIELD, the first T1D Stage 3 disease-modifying medication, can be delayed.
5. Pfizer Inc.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation, founded in 1849 and is headquartered in Williamsburgh, New York. It operates to over 181 countries. In order to potentially treat people with obesity and Type 2 diabetes mellitus (T2DM), Pfizer Inc. (NYSE: PFE) announced that it will continue to advance one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate into additional clinical testing through June 2023.
6. Novartis AG
Novartis AG is a Swiss global pharmaceutical firm headquartered in Basel, Switzerland, that was created in 1996. Novartis AG has around 140 partners worldwide.In August 2021, Novartis announced that the US Food and Drug Administration (FDA) had decided to lift the partial clinical trial hold imposed in October 2019 and permit OAV-101 intrathecal (IT) clinical investigations for patients with spinal muscular atrophy (SMA). Novartis' thorough nonclinical toxicological research in nonhuman primates (NHP) addressed all issues mentioned, including dorsal root ganglia (DRG) damage following IT administration, and the decision to release the hold was based on the research's conclusions.
7. Merck KGaA
Merck KGaA is a German multinational science and technology company, was founded in 1668 and headquartered in Darmstadt, Germany. It operates in 66 countries.
8. Amgen Inc.
Amgen Inc, headquartered in California, is an American international biopharmaceutical business founded in 1980. It has a global footprint and operates in 100 countries.
9. AstraZeneca
AstraZeneca is a worldwide pharmaceutical and biotechnology firm with headquarters in England, UK, which was created in 1999. It actively operates in 100 nations. In order to speed up the research and development of peptide therapies, ProteinQure, a pioneer in computational protein drug discovery, announced a partnership with the multinational biopharmaceutical company AstraZeneca in July 2020. The two companies will use structure-based design to create therapeutic libraries.
Bayer AG is a German multinational pharmaceutical and biotechnology company founded in 1863 and it is one of the largest pharmaceutical companies in the world. The headquarter is in Leverkusen, Germany. Bayer is represented in 83 countries including Canada, Mexico, Germany and Switzerland.
*Definition: Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases. Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives; peptide therapeutics mimic such functions.
